prikaz prve stranice dokumenta Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
  Preuzmi
PDF 726.75 KB
Stručni rad - Stručni rad
Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
Clinical Cardiology, 44 (2021), 8; 1177-1182. https://doi.org/10.1002/clc.23681
Željkovic, Ivan; Brusich, Sandro; Scherr, Daniel; Velagić, Vedran; Traykov, Vassil; Pernat, Andrej; Anić, Ante; Szavits Nossan, Janko; Jan, Matevz; Bakotić, Zoran; Pezo Nikolić, Borka; Radeljić, Vjekoslav; Bojko, Ana; Benko, Ivica; Manola, Šime; Pavlović, Nikola Više autora...

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Željkovic, I., Brusich, S., Scherr, D., Velagić, V., Traykov, V., Pernat, A. ... Pavlović, N. (2021). Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. Clinical Cardiology, 44. (8), 1177-1182. doi: 10.1002/clc.23681

Željkovic, Ivan, et al. "Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy." Clinical Cardiology, vol. 44, br. 8, 2021, str. 1177-1182. https://doi.org/10.1002/clc.23681

Željkovic, Ivan, Sandro Brusich, Daniel Scherr, Vedran Velagić, Vassil Traykov, Andrej Pernat, Ante Anić, et al. "Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy." Clinical Cardiology 44, br. 8 (2021): 1177-1182. https://doi.org/10.1002/clc.23681

Željkovic, I., et al. (2021) 'Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy', Clinical Cardiology, 44(8), str. 1177-1182. doi: 10.1002/clc.23681

Željkovic I, Brusich S, Scherr D, Velagić V, Traykov V, Pernat A, i sur.. Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. Clinical Cardiology [Internet]. 07.2021. [pristupljeno 03.12.2024.];44(8):1177-1182. doi: 10.1002/clc.23681

I. Željkovic, et al., "Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy", Clinical Cardiology, vol. 44, br. 8, str. 1177-1182, Srpanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:626330. [Citirano: 03.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:626330
Podaci o radu
Naslov (engleski)Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
AutorIvan Željkovic
AutorSandro Brusich
AutorDaniel Scherr
AutorVedran Velagić
AutorVassil Traykov
AutorAndrej Pernat
AutorAnte Anić
AutorJanko Szavits Nossan
AutorMatevz Jan
AutorZoran Bakotić
AutorBorka Pezo Nikolić
AutorVjekoslav Radeljić
AutorAna Bojko
AutorIvica Benko
AutorŠime Manola
AutorNikola Pavlović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Periprocedural pulmonary vein isolation (PVI) anticoagulation requires balancing between bleeding and thromboembolic risk. Intraprocedural anticoagulation is monitored by activated clotting time (ACT) with target value >300 s, and there are no guidelines specifying an initial unfractionated heparin (UFH) dose. Methods: We aimed to assess differences in ACT values and UFH dosage during PVI in patients on different oral anticoagulants. We conducted an international, multi-center, registry-based study. Consecutive patients with atrial fibrillation (AF) undergoing PVI, on uninterrupted anticoagulation therapy, were analyzed. Before transseptal puncture, UFH bolus of 100 IU/kg was administered regardless of the anticoagulation drug. Results: Total of 873 patients were included (median age 61 years, IQR 53-66; female 30%). There were 248, 248, 189, 188 patients on warfarin, dabigatran, rivaroxaban, and apixaban, respectively. Mean initial ACT was 257 ± 50 s, mean overall ACT 295 ± 45 s and total UFH dose 158 ± 60 IU/kg. Patients who were receiving warfarin and dabigatran compared to patients receiving rivaroxaban and apixaban had: (i) significantly higher initial ACT values (262 ± 57 and 270 ± 48 vs. 248 ± 42 and 241 ± 44 s, p < .001), (ii) significantly higher ACT throughout PVI (309 ± 46 and 306 ± 44 vs. 282 ± 37 and 272 ± 42 s, p < .001), and (iii) needed lower UFH dose during PVI (140 ± 39 and 157 ± 71 vs. 171 ± 52 and 172 ± 70 IU/kg). Conclusion: There are significant differences in ACT values and UFH dose during PVI in patients receiving different anticoagulants. Patients on warfarin and dabigatran had higher initial and overall ACT values and needed lower UFH dose to achieve adequate anticoagulation during PVI than patients on rivaroxaban and apixaban.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeStručni rad - Stručni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaClinical Cardiology
Brojčani podacivol. 44, br. 8, str. 1177-1182
p-ISSN0160-9289
e-ISSN1932-8737
DOIhttps://doi.org/10.1002/clc.23681
URN:NBNurn:nbn:hr:184:626330
Datum objave publikacije2021-07
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1002/clc.23681
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2021-10-26 11:43:37